Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Q2 2023 Earnings Conference Call May 8, 2023 4:30 PM ET

Company Participants

Jennifer Viera - Investor Relations

Jay Luly - President & Chief Executive Officer

Scott Rottinghaus - Chief Medical Officer

Paul Mellett - Chief Financial Officer

Tara Kieffer - Senior Vice President, New Product Strategy & Development

Conference Call Participants

Yasmeen Rahimi - Piper Sandler

Brian Abrahams - RBC Capital Markets

Roy Buchanan - JMP Securities

Liisa Bayko - Evercore ISI

Brian Skorney - Baird

Thomas Yip - H.C. Wainwright

Roanna Ruiz - SVB Securities

Hannah Adeoye - JPMorgan

Operator

Good afternoon, and welcome to Enanta Pharmaceuticals Fiscal Second Quarter Ended March 31, 2023 Financial Results Conference Call. At this time, all participants are in a listen only mode. There will be a question-and-answer session at the end of prepared remarks. Please be advised that these call is being recorded.

I would now like to turn the conference over to Jennifer Viera, Investor Relations. Please go ahead.

Jennifer Viera

Thank you, operator, and thanks to everyone for joining us this afternoon. The news release with our fiscal second quarter 2023 financial results was issued this afternoon and is available on our website. A news release with top line data from our SPRINT clinical trial was also issued this afternoon and can be found on our website as well. Slides from today's webcast will be available on our website after the call ends.

On the call today are Dr. Jay Luly, our President and Chief Executive Officer; Dr. Scott Rottinghaus, our Chief Medical Officer; Paul Mellett, our Chief Financial Officer; and Dr. Tara Kieffer, our Senior Vice President of New Product Strategy and Development.

Before we begin with our formal remarks, we do want to remind you that we will be making forward-looking statements, which may include our plans and expectations with respect to our research and development pipeline and financial projections, all of which involve certain assumptions and risks beyond our control that could cause our actual developments and results to differ materially from those statements. A description of these risks is in our most recent Form 10-K and other periodic reports filed with the SEC. Enanta does not undertake any obligation to update any forward-looking statements made during this call.

I'd now like to turn the call over to Dr. Jay Luly, Jay?

Jay Luly

Thank you, Jennifer, and good afternoon, everyone. At Enanta our goal has always been to develop curative therapies for patients in need. That effort continues today with our announcement of the top line data from our Phase 2 SPRINT study of EDP-235, our 3CL protease inhibitor in development as an oral once-daily treatment for COVID-19.